Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving gemcitabine, paclitaxel, and doxorubicin
together with pegfilgrastim works in treating patients with metastatic or unresectable
bladder cancer or urinary tract cancer and kidney dysfunction. Drugs used in chemotherapy,
such as gemcitabine, paclitaxel, and doxorubicin, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Colony
stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in
bone marrow or peripheral blood and may help the immune system recover from the side effects
of chemotherapy. Giving combination chemotherapy together with pegfilgrastim may kill more
tumor cells. Chemotherapy drugs may have different effects in patients who have changes in
their kidney function.